Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Shares outstanding
Bio-Techne Corp's shares outstanding at the end of fiscal 2026 was $157.0M, unchanged from fiscal 2025. Over the past ten years it has ranged from $148.9M (fiscal 2015) to $164.1M (fiscal 2022); the current reading is higher than 50% of that period. Bio-Techne Corp ranks 75th of 602 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $157.0M | (1.70%) |
| FY2025 | $159.7M | (0.66%) |
| FY2024 | $160.8M | (0.67%) |
| FY2023 | $161.9M | (1.38%) |
| FY2022 | $164.1M | 1.35% |
| FY2021 | $161.9M | 2.75% |
| FY2020 | $157.6M | 1.31% |
| FY2019 | $155.6M | 2.20% |
| FY2018 | $152.2M | 1.48% |
| FY2017 | $150.0M | 0.47% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $157.0M | (0.25%) |
| Mar 2026 | $157.4M | 0.26% |
| Dec 2025 | $157.0M | 0.41% |
| Sep 2025 | $156.4M | (2.10%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| SMMT Summit Therapeutics PLC compare | $778.2M |
| BBIO BridgeBio Pharma, Inc. compare | $195.8M |
| BMRN BioMarin Pharmaceutical Inc. compare | $194.5M |
| TECH Bio-Techne Corp | $157.0M |
| PCVX Vaxcyte, Inc. compare | $144.5M |
| CORT Corcept Therapeutics Incorporated compare | $118.4M |
| KRYS Krystal Biotech, Inc. compare | $30.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $29.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement